164 related articles for article (PubMed ID: 31333153)
21. Chinese herbal medicine as adjuvant treatment to chemotherapy for multidrug-resistant tuberculosis (MDR-TB): A systematic review of randomised clinical trials.
Wang M; Guan X; Chi Y; Robinson N; Liu JP
Tuberculosis (Edinb); 2015 Jul; 95(4):364-72. PubMed ID: 25861717
[TBL] [Abstract][Full Text] [Related]
22. Multidrug-resistant Mycobacterium tuberculosis: a report of cosmopolitan microbial migration and an analysis of best management practices.
Joean O; Thiele T; Schütz K; Schwerk N; Sedlacek L; Kalsdorf B; Baumann U; Stoll M
BMC Infect Dis; 2020 Sep; 20(1):678. PubMed ID: 32942990
[TBL] [Abstract][Full Text] [Related]
23. "Side effects--part of the package": a mixed methods approach to study adverse events among patients being programmatically treated for DR-TB in Gujarat, India.
Jakasania A; Shringarpure K; Kapadia D; Sharma R; Mehta K; Prajapati A; Kathirvel S
BMC Infect Dis; 2020 Dec; 20(1):918. PubMed ID: 33267826
[TBL] [Abstract][Full Text] [Related]
24. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
[TBL] [Abstract][Full Text] [Related]
25. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study.
Gobena D; Ameya G; Haile K; Abreha G; Worku Y; Debela T
Ann Clin Microbiol Antimicrob; 2018 Jul; 17(1):30. PubMed ID: 29970076
[TBL] [Abstract][Full Text] [Related]
26. Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study.
Hassane-Harouna S; Cherif GF; Ortuno-Gutierrez N; Cisse D; Camara LM; Diallo BD; Camara S; Bangoura AM; Lynen L; Decroo T
PLoS One; 2020; 15(8):e0237355. PubMed ID: 32776969
[TBL] [Abstract][Full Text] [Related]
27. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
[TBL] [Abstract][Full Text] [Related]
28. Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy.
Gualano G; Mencarini P; Musso M; Mosti S; Santangelo L; Murachelli S; Cannas A; Di Caro A; Navarra A; Goletti D; Girardi E; Palmieri F
PLoS One; 2019; 14(2):e0212948. PubMed ID: 30817779
[TBL] [Abstract][Full Text] [Related]
29. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
30. [Management of multidrug-resistant tuberculosis].
Tritar F; Daghfous H; Ben Saad S; Slim-Saidi L
Rev Pneumol Clin; 2015; 71(2-3):130-9. PubMed ID: 25153927
[TBL] [Abstract][Full Text] [Related]
31. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of risk factors associated with drug-resistant tuberculosis in Yemen: data from centres with high drug resistance.
Jaber AAS; Ibrahim B
BMC Infect Dis; 2019 May; 19(1):464. PubMed ID: 31126246
[TBL] [Abstract][Full Text] [Related]
33. Clofazimine in the treatment of multidrug-resistant tuberculosis.
Xu HB; Jiang RH; Xiao HP
Clin Microbiol Infect; 2012 Nov; 18(11):1104-10. PubMed ID: 22192631
[TBL] [Abstract][Full Text] [Related]
34. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis.
Bastos ML; Cosme LB; Fregona G; do Prado TN; Bertolde AI; Zandonade E; Sanchez MN; Dalcolmo MP; Kritski A; Trajman A; Maciel ELN
BMC Infect Dis; 2017 Nov; 17(1):718. PubMed ID: 29137626
[TBL] [Abstract][Full Text] [Related]
35. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009-2013.
Zhang L; Meng Q; Chen S; Zhang M; Chen B; Wu B; Yan G; Wang X; Jia Z
Clin Microbiol Infect; 2018 Apr; 24(4):381-388. PubMed ID: 28712668
[TBL] [Abstract][Full Text] [Related]
36. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
[TBL] [Abstract][Full Text] [Related]
38. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
39. Factors contributing to the high prevalence of multidrug-resistant tuberculosis among previously treated patients: a case-control study from China.
Wang K; Chen S; Wang X; Zhong J; Wang X; Huai P; Wu L; Wang L; Jiang S; Li J; Peng Y; Yao H; Ma W
Microb Drug Resist; 2014 Aug; 20(4):294-300. PubMed ID: 24328894
[TBL] [Abstract][Full Text] [Related]
40. Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis.
Gao J; Ma Y; Du J; Zhu G; Tan S; Fu Y; Ma L; Zhang L; Liu F; Hu D; Zhang Y; Li X; Li L; Li Q
BMC Pulm Med; 2016 Feb; 16():26. PubMed ID: 26846562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
